文献速递胰腺与胆道疾病消化内镜

预测EUS引导下经胃ERCP持续性瘘管发生的因素:多中心匹配病例对照研究

Factors predictive of persistent fistulas in EUS-directed transgastric ERCP: a multicenter matched case-control study.
PubMed 文献 · Gastrointest Endosc · 2022-10-11

多中心匹配病例对照研究纳入9个中心2015年2月至2021年9月数据,比较25例持续性瘘管与50例无瘘管患者,发现LAMS留置时间较长与持续性瘘管风险较高相关,LAMS取出时行APC或一期闭合未显示保护作用,多数持续性瘘管可经内镜闭合有效处理。

要点

  • 持续性瘘管组LAMS平均留置时间显著长于对照组(127天 vs 48天,P=0.02)。
  • 持续性瘘管组总休重增加≥5%者比例高于对照组(33.3% vs 10.3%,P=0.03)。
  • LAMS留置时间>40天为持续性瘘管的显著预测因素(比值比4.5,P=0.01)。

核心结论

  • LAMS留置时间较长与EDGE患者持续性瘘管风险较高相关。
  • LAMS取出时行APC消融或一期闭合未显示对持续性瘘管有保护作用。
  • 持续性瘘管若出现,多数病例可通过内镜闭合有效处理。

研究设计与样本

  • 多中心匹配病例对照研究,纳入9个中心(美国8个,欧洲1个),时间范围2015年2月至2021年9月。
  • 持续性瘘管病例定义为LAMS取出后8周以上内镜或影像学证据显示瘘管存在。
  • 对照定义为LAMS取出后8周以上内镜或影像学确认无瘘管。
  • 25例持续性瘘管病例与50例无瘘管对照按年龄和性别匹配。

主要发现

  • 持续性瘘管组LAMS平均留置时间显著长于对照组(127天 vs 48天,P=0.02)。
  • 持续性瘘管组总休重增加≥5%者比例高于对照组(33.3% vs 10.3%,P=0.03)。
  • 两组基线人口学、瘘管部位、LAMS尺寸或一期闭合频率无差异(P>0.05)。
  • LAMS留置时间>40天为持续性瘘管的显著预测因素(比值比4.5,P=0.01)。
  • LAMS每留置7天,持续性瘘管发生比值增加9.5%;持续性瘘管患者中19例(76%)尝试内镜闭合,14例(73.7%)成功解决。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: EUS-directed transgastric ERCP (EDGE) is an established method for managing pancreaticobiliary pathology in Roux-en-Y gastric bypass patients, with high rates of technical success and low rates of serious adverse events (AEs). However, widespread adoption of the technique has been limited because of concerns about the development of persistent gastrogastric or jejunogastric fistulas. Gastrogastric and jejunogastric fistulas have been reported in up to 20% of cases in some series, but predictive risk factors and long-term management and outcomes are lacking. Therefore, our aims were to assess factors associated with the development of persistent fistulas and the technical success of endoscopic fistula closure. METHODS: This is a case-control study involving 9 centers (8 USA, 1 Europe) from February 2015 to September 2021. Cases of persistent fistulas were defined as endoscopic or imaging evidence of fistula more than 8 weeks after lumen-apposing metal stent (LAMS) removal. Control subjects were defined as endoscopic or imaging confirmation of no fistula more than 8 weeks after LAMS removal. AEs were defined and graded according to the American Society for Gastrointestinal Endoscopy lexicon. RESULTS: Twenty-five patients identified to have evidence of a persistent fistula on follow-up surveillance (cases) were matched with 50 patients with no evidence of a persistent fistula on follow-up surveillance (control subjects) based on age and sex. Mean LAMS dwell time was 74.7 ± 106.2 days. After LAMS removal, argon plasma coagulation (APC) ablation of the fistula was performed in 46 patients (61.3%). Primary closure of the fistula was performed in 26.7% of patients (20: endoscopic suturing in 17, endoscopic tacking in 2, and over-the-scope clips + endoscopic suturing in 1). When comparing cases with control subjects, there was no difference in baseline demographics, fistula site, LAMS size, or primary closure frequency between the 2 groups (P > .05). However, in the persistent fistula group, the mean LAMS dwell time was significantly longer (127 vs 48 days, P = .02) and more patients had ≥5% total body weight gain (33.3% vs 10.3%, P = .03). LAMS dwell time was a significant predictor of persistent fistula (odds ratio, 4.5 after >40 days in situ, P = .01). The odds of developing a persistent fistula increased by 9.5% for every 7 days the LAMS was left in situ. In patients with a persistent fistula, endoscopic closure was attempted in 19 (76%) with successful resolution in 14 (73.7%). CONCLUSIONS: Longer LAMS dwell time was found to be associated with a higher risk of persistent fistulas in EDGE patients. APC or primary closure of the fistula on LAMS removal was not found to be protective against developing a persistent fistula, which, if present, can be effectively managed through endoscopic closure in most cases.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Ghandour B, Keane MG, Shinn B, et al. Factors predictive of persistent fistulas in EUS-directed transgastric ERCP: a multicenter matched case-control study. Gastrointest Endosc. 2022. PMID: 36228699. doi:10.1016/j.gie.2022.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。